on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Partners with Nanosoft for ONC010 Development
Onco-Innovations Limited has announced a new partnership with Nanosoft Polymers to advance the development of their lead compound, ONC010. Under the agreement, Nanosoft will provide key services in polymer process development and drug delivery, aiming to strengthen ONC010's manufacturing and formulation groundwork for future clinical trials.
This collaboration is part of Onco's broader strategy to leverage external expertise in critical development areas. Nanosoft's expertise in polymer synthesis and scale-up will support Onco's goals of GMP readiness and clinical development. The focus will be on establishing a scalable, reproducible manufacturing process and enhancing quality controls.
Onco-Innovations is working with other partners like Dalton Pharma Services and Nucro-Technics on complementary developments, forming a supportive ecosystem for moving ONC010 towards First-in-Human evaluation.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news